$7.56
Today
as of Sep 4, 16:46 ET
Last 30 days
Recent Press Releases & News
Aura Biosciences to Participate in Upcoming Investor Conference
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Aura Biosciences Q2 Loss Widens
Overview
52-week range
$4.73
$9.54
59% of range
Avg surprise (last 3)
-12.6%
Avg reaction (last 2)
+1.6%
50% positive
Latest IV / EM
35%
EM ±6.3% · $7 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.48 | — | — | — | — | financials |
| Mon May 11, 2026 | Mar/2026 | $-0.50 | $-0.40 | -25.0% | +9.1% | -2.5% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.40 | — | — | — | — | financials |
| Wed Aug 13, 2025 | Jun/2025 | $-0.47 | $-0.49 | +4.1% | — | — | earnings |
| Thu May 15, 2025 | Mar/2025 | $-0.55 | $-0.47 | -17.0% | — | +5.7% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.42 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.41 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.40 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.48 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.48 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.46 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-48M | $-35M | — | $-28M | $-29M | $-29M | — | $-23M |
| Net income | $-46M | $-34M | — | $-26M | $-27M | $-27M | — | $-21M |
| EPS (diluted) | $-0.48 | $-0.50 | — | $-0.40 | $-0.47 | $-0.55 | — | $-0.42 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $68M | $85M | $60M | $48M | $107M | $38M | $32M | $25M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $329M | $119M | $150M | $170M | $184M | $135M | $161M | $183M |
| Total assets | $348M | $138M | $169M | $190M | $204M | $155M | $183M | $205M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $33M | $30M | $33M | $33M | $30M | $27M | $31M | $31M |
| Total equity | $315M | $107M | $137M | $157M | $175M | $128M | $152M | $175M |